Abstract
Abstract
Objective
Preoperative radiotherapy has been used with high-grade bulky tumors or tumors close to neurovascular structures in patients with osteosarcoma. Hypofractionated radiotherapy protocols have been recently preferred upon understanding its similar efficacy and non-increased adverse effects. We aimed to evaluate the impact of preoperative hypofractionated radiotherapy in patients with primary or recurrent osteogenic osteosarcoma.
Methods
A single-center, retrospective study was performed on patients with primary or recurrent osteogenic osteosarcoma who underwent preoperative hypofractionated radiotherapy between 2014 and 2020. The patients preoperatively received a total dose of 30 to 35 Gy with ten fractions. The demographic and clinical characteristics of the patients were recorded. The patients were grouped as good (necrosis rate of ≥ 90%) and poor responders (necrosis rate of < 90%). Survival rates, including recurrence-free, metastasis-free, and overall, were calculated.
Results
There were 20 patients with a median age of 17 years. Negative surgical borders were obtained in 88.9% of 18 patients amenable to limb-sparing surgery after preoperative radiotherapy. The median percentage of necrosis was 88.5%, ranging from 30–100%. Half of the patients (50.0%) were good responders. There were two local recurrences (10.0%) and nine metastasis (45.0%). The lungs were the most common for metastasis (40%). The overall mortality and five-year survival rates were 40.0% and 45.0%. The median recurrence-free, metastasis-free, and overall survival were 49.4, 34.4, and 56.1, respectively.
Conclusion
Preoperative hypofractionated radiotherapy with or without chemotherapy might be a treatment modality in osteosarcoma patients for limb-conserving or that are resectable but hard to achieve clean margins due to local involvement.
Publisher
Research Square Platform LLC
Reference26 articles.
1. Hız M, Karaismailoglu B, Ulutas S, Camurdan VB, Gorgun B, Oner Dincbas F. The effect of preoperative radiotherapy on local control and prognosis in high-grade non-metastatic intramedullary osteosarcoma of the extremities. Arch Orthop Trauma Surg. 2021;141(7):1083–1089. doi: 10.1007/s00402-020-03494-4. PMID: 32506177.
2. Belayneh R, Fourman MS, Bhogal S, Weiss KR. Update on Osteosarcoma. Curr Oncol Rep. 2021;23(6):71. doi: 10.1007/s11912-021-01053-7. PMID: 33880674.
3. Clinical Outcome Following Prolonged Neoadjuvant Chemotherapy and Delayed Surgery in Osteosarcoma Patients: An Evidence-based Clinical Review;Sugito W;Acta Med Indones,2022
4. Long-term results of extremİty soft tİssue sarcomas lİmb-sparİng surgery and radİotherapy;Dogan OY;Acta Ortop Bras,2019
5. Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer Treat Res. 2009;152:147 – 64. doi: 10.1007/978-1-4419-0284-9_7. PMID: 20213389.